Erratum: Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction (Journal of General Virology (2007) vol. 88 ( 1) (1-12))

Бібліографічні деталі
Автори:	Hanke, T, Goonetilleke, N, McMichael, A, Dorrell, L
Формат:	Journal article
Мова:	English
Опубліковано:	2008

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.
за авторством: Hanke, T, та інші
Опубліковано: (2007)

Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.
за авторством: Dorrell, L, та інші
Опубліковано: (2006)

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.
за авторством: Mwau, M, та інші
Опубліковано: (2004)

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
за авторством: Hanke, T, та інші
Опубліковано: (1998)

Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial
за авторством: Hayton, E, та інші
Опубліковано: (2014)

Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.
за авторством: Emma-Jo Hayton, та інші
Опубліковано: (2014-01-01)

Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.
за авторством: Dorrell, L, та інші
Опубліковано: (2007)

Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-gamma ELISPOT assay.
за авторством: Winstone, N, та інші
Опубліковано: (2009)

Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro.
за авторством: Dorrell, L, та інші
Опубліковано: (2000)

Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses.
за авторством: Ondondo, B, та інші
Опубліковано: (2006)

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.
за авторством: Howles, S, та інші
Опубліковано: (2010)

Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.
за авторством: Goonetilleke, N, та інші
Опубліковано: (2006)

Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen.
за авторством: Hanke, T, та інші
Опубліковано: (1999)

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
за авторством: McConkey, S, та інші
Опубліковано: (2003)

Induction of human immunodeficiency virus type 1-specific T cells by a bluetongue virus tubule-vectored vaccine prime-recombinant modified virus Ankara boost regimen.
за авторством: Larke, N, та інші
Опубліковано: (2005)

DNA vaccines against human immunodeficiency virus type 1.
за авторством: Estcourt, M, та інші
Опубліковано: (2004)

Clinical development of Modified Vaccinia virus Ankara vaccines.
за авторством: Gilbert, S
Опубліковано: (2013)

Clinical development of Modified Vaccinia virus Ankara vaccines
за авторством: Gilbert, S
Опубліковано: (2013)

Distinct recognition of non-clade B human immunodeficiency virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa.
за авторством: Dorrell, L, та інші
Опубліковано: (1999)

Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.
за авторством: Cebere, I, та інші
Опубліковано: (2006)

Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya.
за авторством: Hanke, T, та інші
Опубліковано: (2002)

Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity.
за авторством: Sharpe, S, та інші
Опубліковано: (2001)

Cytotoxic T-cell response to simian immunodeficiency virus by cynomolgus macaque monkeys immunized with recombinant vaccinia virus.
за авторством: Gotch, F, та інші
Опубліковано: (1991)

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
за авторством: Caroline Staib, та інші
Опубліковано: (2003-04-01)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
за авторством: Olga Vladimirovna Orlova, та інші
Опубліковано: (2022-09-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
за авторством: Volker Sandig, та інші
Опубліковано: (2013-11-01)

Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara.
за авторством: Sharpe, S, та інші
Опубліковано: (2003)

Monocytes Phenotype and Cytokine Production in Human Immunodeficiency Virus-1 Infected Patients Receiving a Modified Vaccinia Ankara-Based HIV-1 Vaccine: Relationship to CD300 Molecules Expression
за авторством: Joana Vitallé, та інші
Опубліковано: (2017-07-01)

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
за авторством: Gilbert, S, та інші
Опубліковано: (1999)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
за авторством: Juan García-Arriaza, та інші
Опубліковано: (2021-08-01)

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
за авторством: Rosario, M, та інші
Опубліковано: (2010)

Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored ebola vaccines at 1 year
за авторством: Winslow, R, та інші
Опубліковано: (2017)

Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant
за авторством: Ning Yang, та інші
Опубліковано: (2022-10-01)

Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants.
за авторством: Slyker, J, та інші
Опубліковано: (2005)

Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity.
за авторством: Annett Hessel, та інші
Опубліковано: (2011-01-01)

Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara
за авторством: C. Staib, та інші
Опубліковано: (2000-06-01)

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
за авторством: Kaïdre Bendjama, та інші
Опубліковано: (2017-09-01)

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
за авторством: Malachy I. Okeke, та інші
Опубліковано: (2017-10-01)

Cytotoxic T lymphocytes recognize structurally diverse, clade-specific and cross-reactive peptides in human immunodeficiency virus type-1 gag through HLA-B53.
за авторством: Dorrell, L, та інші
Опубліковано: (2001)

Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.
за авторством: Jaoko, W, та інші
Опубліковано: (2008)

Erratum: Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction (Journal of General Virology (2007) vol. 88 ( 1) (1-12))

Схожі ресурси

Схожі ресурси